1
Olaf B Kinstler, Nancy E Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Robert B Winter, Karol M Pessin, Steven M Odre, October 20, 1998: US05824784 (274 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


2
Olaf B Kinstler, Nancy E Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Craig A Crandall, Ron K Levy, Steven M Odre, November 16, 1999: US05985265 (88 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of ...


3
Olaf B Kinstler, Nancy Elise Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Marshall Gerstein & Borun, February 16, 2010: US07662933 (29 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


4
Olaf B Kinstler: N-terminally chemically modified protein compositions and methods. Amgen, Marshall Gerstein & Borun, October 18, 2005: US06956027 (8 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of ...


5
Nancy E Gabriel, Christine E Farrar: N-terminally chemically modified protein compositions and methods. Amgen, Marshall Gerstein & Borun, August 15, 2006: US07090835 (4 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


6
Kinstler Olaf B, Gabriel Nancy E, Farrar Christine E, Deprince Randolph B: N-terminally chemically modified protein compositions and methods. Amgen, September 25, 1996: EP0733067-A1 (3 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


7
Olaf B Kinstler, Nancy Elise Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Marshall Gerstein & Borun, September 4, 2012: US08258262

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


8
Justin K Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M Tegley, James R Falsey, Elizabeth M Doherty, Leslie P Miranda: 1.7, Potent and selective inhibitors of NA. AMGEN, Angela L Purcell, May 2, 2017: US09636418

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pha ...


9
Justin K Murray, Leslie P Miranda, Stefan I McDonough: 1.7, 1.3 and NA, Potent and selective inhibitors of NA. AMGEN, Angela L Purcell, October 24, 2017: US09796766

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of ...


10
Kinstler Olaf B, Gabriel Nancy E, Farrar Christine E, Deprince Randolph B: Compositions de proteines ayant subi une modification chimique a lextremite n-terminale et procedes, N-terminally chemically modified protein compositions and methods. Amgen, GOWLING LAFLEUR HENDERSON, April 25, 1996: CA2178752

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant co mpositions, including novel N-terminally chemically modified G-CSF compositions and relat ...